Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $56.5052W HIGH $101.40
Volume
1.89 M
Value Traded
257.07 M
Short % Float
6.1%
-3%Week
-1.6%1 Month
-6.12%3 Month
-18.9%6 Month
+18.22%5 Year
+547.4%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.85 B
EPS (TTM)
3.99
P/E Ratio
18.39
Ent. Value
9.00 B
Total Shares
134.26 M
Float Shares
111.00 M
Insiders
17.32%
Institutions
89.74%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
GMED Catalyst Timeline
Dated clinical, regulatory and corporate events for Globus Medical, Inc.
Past FDA Catalysts and PDUFA Decisions
How GMED actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 80%
Mid Cap(rank 527 of 658)
Percentile Rank
Globus Medical, Inc. faces pipeline headwinds (26/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every GMED program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TOBIN JAMES RDirector | Option | 15,000 30,000 held | $63.68 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GMED
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 1.3 % (-55.2 %) | 37.05 M | 468.92 K | -47.13% ( -418.08 K) |
GMED Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GMED ranks across every disease it competes in
Competitive Position is a premium feature
See how GMED ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGMED News
GMEDGlobus Medical Announces CE Mark for Excelsius3D™ Imaging System
Globus Medical has announced that its Excelsius3D™ imaging system has received CE marking for commercial sale in the European Union and the United Kingdom. This intelligent imaging platform combines 3D cone-beam CT, 2D fluoroscopy, and digital radiography, enhancing the capabilities of the ExcelsiusGPS™ robotic navigation system. The CE mark allows for broader commercialization of the system across Europe.
Read more →GMEDGlobus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions
Globus Medical has acquired Higgs Boson Health, a digital healthcare company, to enhance its offerings in musculoskeletal technology. This acquisition aims to improve patient and provider experiences through AI-driven solutions. The integration is expected to foster continuous learning and improve outcomes in musculoskeletal surgeries.
Read more →GMEDGlobus Medical Reports Second Quarter 2026 Results
Globus Medical reported a 5.9% increase in worldwide net sales for Q2 2026, totaling $789.6 million. Non-GAAP diluted EPS rose significantly by 55.8%, while GAAP net income decreased by 25.3% due to a prior year gain from an acquisition. The company continues to show strong growth in its US Spine and International Spine segments and reaffirms its revenue guidance for the year.
Read more →GMEDGlobus Medical Schedules Second Quarter Earnings Release and Conference Call
Globus Medical, Inc. will release its financial results for the second quarter of 2026 on August 6, after market close. A teleconference is scheduled for the same day at 4:30 p.m. ET to discuss the results with investors. The audio archive will be available on their website following the call.
Read more →GMEDGlobus Medical Reports First Quarter 2026 Results AUDUBON, PA.
Globus Medical, Inc. announced its financial results for the first quarter of 2026, reporting a total revenue increase of 27% to $759.9 million compared to the same quarter in 2025. The company achieved a GAAP net income of $124.3 million, representing a significant 64.7% increase. Organic growth in the core spine market was highlighted, with overall procedural volume strength contributing to the positive results. The firm has reaffirmed its full-year 2026 revenue guidance while raising its forecast for non-GAAP fully diluted EPS.
Read more →GMEDGlobus Medical Reports First Quarter 2026 Results
Globus Medical, Inc. reported a strong financial performance for Q1 2026, with worldwide net sales reaching $759.9 million, a 27% increase year-over-year. The company achieved record earnings, with GAAP diluted EPS rising to $0.90, marking a 66.6% increase. The growth was driven by strong performance in core spine and the integration of Nevro. The company reaffirmed its full-year revenue guidance of $3.18 billion to $3.22 billion.
Read more →GMEDGlobus Medical Schedules First Quarter Earnings Release and Conference Call
Globus Medical, Inc. will release its financial results for Q1 2026 on May 7, 2026. Following the announcement, a teleconference will be held to discuss the results with investors. Participants can join via webcast or telephone, with an audio archive available afterward. The company emphasizes its dedication to addressing clinical needs in musculoskeletal technology.
Read more →GMEDGlobus Medical Announces Board Departure
Globus Medical, Inc. announced the immediate departure of John A. DeFord, PhD, from its Board of Directors. He will not seek re-election at the upcoming Annual Meeting of Stockholders. The company expressed gratitude for his contributions, particularly during the merger with NuVasive, and wished him success in future endeavors.
Read more →GMEDGlobus Medical, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Globus Medical, Inc. amidst allegations of possible securities fraud affecting investors. The investigation follows a significant stock price decline after the FDA issued a warning regarding concerns over the company’s Class II Excelsius GPS surgical robot. Investors are being encouraged to seek legal recourse through the firm, which has a history of recovering substantial amounts for clients. This situation raises concerns regarding the company's compliance with quality regulatory standards.
Read more →GMEDGlobus Medical Reports Fourth Quarter and Full Year 2025 Results
Globus Medical reported strong financial results for Q4 and full year 2025, with significant growth in sales and earnings. The company achieved a 25.7% increase in worldwide net sales for Q4 and an 18.4% increase for the full year. The integration of Nevro contributed positively to their performance, and they provided optimistic guidance for 2026.
Read more →GMEDGlobus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
Globus Medical, Inc. (NYSE:GMED) will release its financial results for the fourth quarter and full year ended December 31, 2025 on February 24, 2026, post market close. Following the announcement, a teleconference will occur at 4:30 p.m. Eastern Time to discuss performance with investors. The company emphasizes its role as a leading provider of musculoskeletal solutions and mentions the availability of the release and conference call via its website.
Read more →GMEDGlobus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
Globus Medical, Inc. reported preliminary unaudited sales results showing a substantial increase in sales for the fourth quarter and full year of 2025. Fourth quarter sales are expected to reach approximately $823.2 million, marking a 25.2% growth compared to the same period in 2024, while full year sales are projected at around $2.936 billion, reflecting a 16.5% increase. The company expressed confidence in sustaining this momentum into 2026, amidst integration efforts of recent acquisitions. However, the results are preliminary and subject to revision pending final audits.
Read more →GMED▲ +35.9%on this news
Globus Medical Reports Third Quarter 2025 Results
Globus Medical, Inc. reported strong financial results for Q3 2025, with a 23% increase in revenue driven by growth in its US Spine business and the successful integration of the Nevro acquisition. The company achieved record non-GAAP free cash flow and significantly improved earnings per share. Looking ahead, Globus Medical has raised its revenue and earnings guidance for the full year.
Read more →GMEDGlobus Medical Reports Third Quarter 2025 Results AUDUBON, PA, November 6, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025.
Globus Medical, Inc. reported its financial results for Q3 2025, showcasing a 23% revenue increase primarily due to growth in its US Spine business. The acquisition of Nevro has positively impacted revenue and is expected to contribute to future earnings. The company's non-GAAP earnings per share rose significantly, reaching $1.18, a 42.6% increase from the previous year. Looking forward, Globus Medical has raised its annual revenue guidance, signifying confidence in sustained growth and operational efficiency.
Read more →GMEDGlobus Medical Schedules Third Quarter Earnings Release and Conference Call
Globus Medical, Inc. will release its financial results for the third quarter of 2025 on November 6, after market close. A teleconference will follow at 4:30 p.m. ET to discuss the results with investors. Participants can join via webcast or telephone, with registration required for the latter. The audio archive will be available post-call.
Read more →GMEDGlobus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma
Globus Medical has launched the ANTHEM™ Elbow Fracture System, a comprehensive plating portfolio aimed at treating a variety of elbow fractures. The system features anatomically contoured plates and polyaxial locking technology, enhancing surgical flexibility and precision. Surgeons have praised its design for improving fixation and minimizing disruption during procedures. This launch underscores Globus Medical's commitment to advancing trauma care.
Read more →GMEDGlobus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.
Globus Medical, Inc. announced a favorable jury verdict in its patent litigation against Life Spine, Inc., confirming that Life Spine's Prolift implants infringed on Globus's patents. The jury awarded Globus lost profits and reasonable royalties. This decision reinforces Globus's commitment to protecting its intellectual property and innovation in spinal surgery technologies.
Read more →About Globus Medical, Inc.
Headquarters2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA, 19403
BIOPHARMAWATCH ELITE PLUS
Trade the next GMED catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime